The Cooper Companies, Inc. (COO) EBITDA Margin: 25.74%
Is The Cooper Companies, Inc.’s EBITDA margin high or low?
The Cooper Companies, Inc.'s EBITDA margin of 25.74% is in line with its 5-year average of 26.16%, around the middle of its 5-year range (24.29%–28.19%).
As of Sunday, June 14, 2026. 3.32% below its 12-month average of 26.63%.
COO EBITDA Margin Chart
COO Average EBITDA Margin Chart
COO Current vs Average EBITDA Margin Chart
COO EBITDA Margin Metrics
EBITDA MARGIN
25.74%
EBITDA MARGIN AVG TTM
26.63%
EBITDA MARGIN AVG 3Y
26.11%
EBITDA MARGIN AVG 5Y
26.16%
EBITDA MARGIN AVG 10Y
26.74%
EBITDA MARGIN AVG 15Y
26.30%
EBITDA MARGIN AVG 20Y
24.93%
CURRENT VS TTM AVG
-3.32%
CURRENT VS 3Y AVG
-1.44%
CURRENT VS 5Y AVG
-1.59%
CURRENT VS 10Y AVG
-3.76%
CURRENT VS 15Y AVG
-2.14%
CURRENT VS 20Y AVG
+3.25%
COO Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Cooper Companies, Inc. (COO) | $13.24B | 25.74% | 26.63% | 26.11% | 26.16% |
| Solventum Corporation (SOLV) | $13.66B | 30.62% | 24.56% | 26.05% | 27.07% |
| Align Technology, Inc. (ALGN) | $12.52B | 18.98% | 19.70% | 20.24% | 21.46% |
| Baxter International Inc. (BAX) | $10.77B | 6.81% | 8.65% | 4.13% | 9.00% |
| Walgreens Boots Alliance, Inc. (WBA) | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Hologic, Inc. (HOLX) | $16.97B | 24.97% | 28.56% | 32.04% | 36.42% |
| Charles River Laboratories International, Inc. (CRL) | $9.03B | 10.23% | 12.29% | 18.59% | 20.64% |
| Tempus AI, Inc. (TEM) | $8.35B | -17.48% | -52.76% | -51.11% | -63.28% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.73B | 48.39% | -17.53% | -54.94% | 28.49% |
| Moderna, Inc. (MRNA) | $19.80B | -131.33% | -118.72% | -58.16% | -40.65% |
Margin Comparison
Gross Margin
64.4%
EBITDA Margin
25.7%
Operating Margin
11.8%
Net Margin
5.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
The Cooper Companies, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
The Cooper Companies, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for The Cooper Companies, Inc. (COO)?
- The EBITDA margin for COO stock is 25.74%.
- Is The Cooper Companies, Inc.'s EBITDA margin high or low?
- The Cooper Companies, Inc.'s EBITDA margin of 25.74% is in line with its 5-year average of 26.16%, around the middle of its 5-year range (24.29%–28.19%).
- What is the TTM average EBITDA margin for The Cooper Companies, Inc. (COO)?
- The TTM average EBITDA margin for COO stock is 26.63%.
- What is the 3Y average EBITDA margin for The Cooper Companies, Inc. (COO)?
- The 3Y average EBITDA margin for COO stock is 26.11%.
- What is the 5Y average EBITDA margin for The Cooper Companies, Inc. (COO)?
- The 5Y average EBITDA margin for COO stock is 26.16%.
- What is the 10Y average EBITDA margin for The Cooper Companies, Inc. (COO)?
- The 10Y average EBITDA margin for COO stock is 26.74%.
- What is the 15Y average EBITDA margin for The Cooper Companies, Inc. (COO)?
- The 15Y average EBITDA margin for COO stock is 26.30%.
- What is the 20Y average EBITDA margin for The Cooper Companies, Inc. (COO)?
- The 20Y average EBITDA margin for COO stock is 24.93%.
The Cooper Companies, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-10-31 | 25.74% |
| 2024-10-31 | 27.51% |
| 2023-10-31 | 24.65% |
| 2022-10-31 | 26.56% |
| 2021-10-31 | 28.19% |
| 2020-10-31 | 24.29% |
| 2019-10-31 | 31.14% |
| 2018-10-31 | 27.23% |
| 2017-10-31 | 28.79% |
| 2016-10-31 | 26.44% |
| 2015-10-31 | 23.65% |
| 2014-10-31 | 25.77% |
| 2013-10-31 | 28.14% |
| 2012-10-31 | 27.57% |
| 2011-10-31 | 23.16% |
| 2010-10-31 | 22.02% |
| 2009-10-31 | 23.28% |
| 2008-10-31 | 19.67% |
| 2007-10-31 | 14.73% |
| 2006-10-31 | 21.06% |
| 2005-10-31 | 23.92% |
| 2004-10-31 | 27.01% |
| 2003-10-31 | 26.17% |
| 2002-10-31 | 24.84% |
| 2001-10-31 | 28.03% |
| 2000-10-31 | 28.18% |
| 1999-10-31 | 28.58% |
| 1998-10-31 | 25.95% |
| 1997-10-31 | 17.03% |
| 1996-10-31 | 16.13% |
Related Metrics
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White